JP2003515601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003515601A5 JP2003515601A5 JP2001541898A JP2001541898A JP2003515601A5 JP 2003515601 A5 JP2003515601 A5 JP 2003515601A5 JP 2001541898 A JP2001541898 A JP 2001541898A JP 2001541898 A JP2001541898 A JP 2001541898A JP 2003515601 A5 JP2003515601 A5 JP 2003515601A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- carbon atoms
- independently
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 34
- 150000003839 salts Chemical class 0.000 description 33
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000004475 heteroaralkyl group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 229960005520 bryostatin Drugs 0.000 description 4
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- -1 hydroxyl compound Chemical class 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16818199P | 1999-11-30 | 1999-11-30 | |
| US60/168,181 | 1999-11-30 | ||
| PCT/US2000/032896 WO2001040214A1 (en) | 1999-11-30 | 2000-11-30 | Bryostatin analogues, synthetic methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003515601A JP2003515601A (ja) | 2003-05-07 |
| JP2003515601A5 true JP2003515601A5 (cg-RX-API-DMAC7.html) | 2008-01-24 |
Family
ID=22610449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541898A Pending JP2003515601A (ja) | 1999-11-30 | 2000-11-30 | ブリオスタチンアナログ、合成方法および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6624189B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1233956A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003515601A (cg-RX-API-DMAC7.html) |
| AU (1) | AU784589B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2393026A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001040214A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256286B2 (en) * | 1999-11-30 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| US7232842B2 (en) * | 2003-01-10 | 2007-06-19 | Board Of Trustees Of The Leland Stanford Junior University | Kinase inhibitors and associated pharmaceutical compositions and methods of use |
| WO2004074249A2 (en) * | 2003-02-20 | 2004-09-02 | Board Of Regents, University Of Texas System | Synthesis of peloruside a and analogs thereof for use as antitumor agents |
| TW201207390A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
| US20070026488A1 (en) * | 2005-07-27 | 2007-02-01 | Targett Nancy M | Biosynthesis of bryostatins by polyketide synthases (PKS) |
| CA2617003A1 (en) | 2005-07-29 | 2007-02-08 | Blanchette Rockefeller Neurosciences Institute | Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| JP4710698B2 (ja) * | 2006-04-10 | 2011-06-29 | 宇部興産株式会社 | シリルエーテル基を有するβ−ジケトン化合物の製造法 |
| KR20090038478A (ko) | 2006-07-28 | 2009-04-20 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 세포 성장 자극, 시냅스 리모델링 및 장기간 기억 강화 방법 |
| US20080058396A1 (en) * | 2006-07-28 | 2008-03-06 | Alkon Daniel L | Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory |
| US9974832B2 (en) * | 2007-02-09 | 2018-05-22 | Cognitive Research Enterprises, Inc. | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| US8497385B2 (en) * | 2007-08-31 | 2013-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| WO2009052507A1 (en) * | 2007-10-19 | 2009-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| JP6446624B2 (ja) | 2010-07-08 | 2019-01-09 | アルコン、ダニエル・エル． | 脳卒中の治療法におけるｐｋｃ活性化因子および抗凝血剤 |
| EP2605773A1 (en) | 2010-08-19 | 2013-06-26 | Blanchette Rockefeller Neurosciences, Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| US10821079B2 (en) | 2011-11-13 | 2020-11-03 | Cognitive Research Enterprises, Inc. | PKC activators and combinations thereof |
| JP6563193B2 (ja) | 2011-11-13 | 2019-08-21 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Ｄｃｐｌａのエステル、およびそれを用いた処置の方法 |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| US9816066B2 (en) | 2012-04-24 | 2017-11-14 | The Regents Of The University Of California | Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters |
| US20150291616A1 (en) * | 2012-11-27 | 2015-10-15 | Aphios Corporation | Bryoid compositions, methods of making and use thereof |
| JP6579956B2 (ja) | 2012-11-28 | 2019-09-25 | アフィオス コーポレーション | 神経変性疾患および他の疾患の治療のための併用治療薬および方法 |
| CA2906164A1 (en) | 2013-03-15 | 2014-09-18 | Daniel L. Alkon | Methods for identifying neuroprotective pkc activators |
| WO2015160851A1 (en) | 2014-04-18 | 2015-10-22 | Neurotrope Bioscience | Methods and compositions for treatment of lipid storage disorders |
| CA2985625A1 (en) | 2015-05-11 | 2016-11-17 | Alkon, Daniel L. | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele |
| US20180256537A1 (en) | 2015-09-23 | 2018-09-13 | Tapan K. Khan | Methods for survival and rejuvenation of dermal fibroblasts using pkc activators |
| US20180311209A1 (en) | 2015-10-08 | 2018-11-01 | Cognitive Research Enterprises, Inc. | Dosing regimens of pkc activators |
| EP3501519B1 (en) | 2016-08-18 | 2024-11-20 | National University Corporation Nara Institute of Science and Technology | Bryostatin 1 for use in treating ige mediated allergic diseases |
| US10947221B2 (en) * | 2016-10-05 | 2021-03-16 | The Board Of The Leland Stanford Junior University | Bryostatin compounds and methods of preparing the same |
| AU2018246378A1 (en) | 2017-03-31 | 2019-10-17 | Cellectis Sa | New universal chimeric antigen receptor T cells specific for CD22 |
| WO2018187647A1 (en) | 2017-04-06 | 2018-10-11 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of neurological diseases, disorders, or conditions |
| EP3964210A1 (en) | 2018-05-18 | 2022-03-09 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
| US20220133687A1 (en) * | 2020-11-02 | 2022-05-05 | Synaptogenix, Inc. | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds |
| JP2023553815A (ja) | 2020-11-24 | 2023-12-26 | ライエル・イミュノファーマ・インコーポレイテッド | 幼若化したｔ細胞を作製する方法、それを含む組成物、及びその使用方法 |
| CN113773256B (zh) * | 2021-09-16 | 2022-11-18 | 精华制药集团南通有限公司 | 一种琥布宗的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560774A (en) | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| US4611066A (en) * | 1984-08-10 | 1986-09-09 | Arizona State University | Bryostatins 4 to 8 |
| US5891870A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
| US4833257A (en) * | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| WO1997034598A1 (en) | 1996-03-20 | 1997-09-25 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating cancer using c-26 modified bryostatin |
-
2000
- 2000-11-30 JP JP2001541898A patent/JP2003515601A/ja active Pending
- 2000-11-30 CA CA002393026A patent/CA2393026A1/en not_active Abandoned
- 2000-11-30 AU AU19440/01A patent/AU784589B2/en not_active Ceased
- 2000-11-30 WO PCT/US2000/032896 patent/WO2001040214A1/en not_active Ceased
- 2000-11-30 US US09/728,929 patent/US6624189B2/en not_active Expired - Lifetime
- 2000-11-30 EP EP00982401A patent/EP1233956A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003515601A5 (cg-RX-API-DMAC7.html) | ||
| WO2009009501A4 (en) | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | |
| RU95113148A (ru) | Производное 2-(2-амино-1,6-дигидро-6-оксопурин-9-ил)-метокси-1,3-пропандиола | |
| JP2006507220A5 (cg-RX-API-DMAC7.html) | ||
| JP2002539181A5 (cg-RX-API-DMAC7.html) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JPH0776174B2 (ja) | 医薬組成物および処置法 | |
| CA2434028A1 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| WO2005000353A1 (ja) | 血清コレステロール低下剤或はアテローム性動脈硬化症の予防又は治療剤 | |
| JP2004531478A5 (cg-RX-API-DMAC7.html) | ||
| US4599355A (en) | Treatment of sleep disorders | |
| ATE111353T1 (de) | Makrolide zur behandlung reversibler obstruktiver atemwegserkrankungen. | |
| EP2139463B1 (en) | Anti-infective agents | |
| JP2005532397A5 (cg-RX-API-DMAC7.html) | ||
| CA1336503C (en) | Use of 5-heteroaryl- or 5-aryl-substituted imidazo[2,1-a] isoquinolines | |
| CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| CN1466465A (zh) | 肥胖或脂肪肝的预防或治疗药物 | |
| JP2002523496A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021093839A5 (cg-RX-API-DMAC7.html) | ||
| JPH0269417A (ja) | 精神分裂病治療用組成物 | |
| RU2001104880A (ru) | Пиперазиновые производные, обладающие антидиабетической активностью, способы их получения и содержащие их композиции | |
| CZ20021435A3 (cs) | Pro-léčiva 6-methoxy-2-naftyloctové kyseliny | |
| US8153687B2 (en) | Gallium complexes with polyalcohols and methods of use | |
| US8389732B2 (en) | Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives |